Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (594)	4/13/1997 7:03:00 PM
From: scaram(o)uche	of 6136

As biotech and broader market indeces have taken a hit this week, AGPH has been holding up pretty well. I'm a happy camper. I don't know what's happening with the general HIV+ population, but there sure are a lot of cyber-savvy patients that are switching to nelf from crix. There was a recent "letter to the editor" in Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 14: 296-297 (1997) that discusses, in warm climates, a very high frequency of crix crystalization in the urine. Of 14 patients studied, seven developed "symptomatic nephrolithiasis, manifested as acute flank or groin pain associated with microscopic and sometimes even gross hematuria."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next